Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir Pilot Trial in IPF
NCT02871401Phase 1Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Valganciclovir Arm with Placebo Arm (2 arms). Primary endpoint: Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events at 12 weeks. Started Jan 2018; status: completed.
02
Drugs
valganciclovir
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02871401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871401.